Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, phase 2 study to evaluate the safety and efficacy of glufosfamide in the treatment of patients with recurrent sensitive small cell lung carcinoma

Next Previous
X
Search
Trial Profile

An open-label, phase 2 study to evaluate the safety and efficacy of glufosfamide in the treatment of patients with recurrent sensitive small cell lung carcinoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glufosfamide (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Threshold Pharmaceuticals

    • Most Recent Events

    • 05 Dec 2007 Status changed from in progress to discontinued.
    • 15 Oct 2007 Enrolment into the trial has been stopped due to a low clinical response rate in the initial 21 patients. Currently enrolled patients will be given the option to continue in the trial.
    • 11 Oct 2007 Status change from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top